Treatment.com AI Stock Price, News & Analysis

Treatment.com International Inc. (CSE: TRUE; OTC: TREIF) is advancing healthcare with its newly launched Treatment Digital Health App, gaining five-star ratings on both Apple and Google platforms. Users, including medical professionals, praise its comprehensive and accurate health assessments. The app is powered by a robust AI-driven Global Library of Medicine, designed to deliver innovative health insights. CEO John Fraser emphasizes the company's commitment to support the medical community and enhance patient care through technology.

Treatment.com International Inc. (CSE: TRUE; OTC: TREIF) announced a non-brokered private placement to raise up to $1,250,000 through unsecured convertible debentures. Each debenture will have an 8% interest rate, maturing in 36 months, and is convertible into units at a price of $0.41. Investors will receive interest payments monthly, with the option to be paid in company units. The funds will be used for general working capital. The units issued upon conversion will be subject to a 12-month hold period.

Treatment.com International Inc. (CSE: TRUE; OTC: TREIF) launched its Treatment Digital Health App on the Google Play Store, expanding access to its innovative AI-driven healthcare technology. The app, initially available on the Apple App Store, is designed to assist users in making informed health decisions with advanced medical knowledge. The launch aligns with the increasing demand for credible health information, particularly during the COVID era. CEO John Fraser and Chief Strategy Officer Dr. Paul A. Markham emphasized the app's groundbreaking capabilities compared to typical online health searches.

Treatment.com International Inc. (CSE: TRUE; OTC: TREIF) has officially launched the Treatment Digital Health App, now available on the Apple App Store. This innovative app utilizes a next-generation AI platform, offering users advanced symptom assessment tools built by a team of medical professionals and engineers. The app's technology is designed to provide accurate health insights, leveraging the Global Library of Medicine (GLM) for up-to-date medical information. The CEO emphasizes the app's role in enhancing healthcare decision-making during the pandemic, aiming for improved individual health outcomes.

Treatment.com International (CSE: TRUE, OTC: TREIF) has announced a research project agreement with the University of Minnesota to add over 220 dermatologic diseases to its AI engine, the Global Library of Medicine (GLM). This collaboration aims to enhance the accuracy of the GLM, supporting the upcoming Treatment Mobile app release. According to Treatment's Chief Medical Officer, the partnership will leverage the University’s expertise to improve skin disease descriptions, thereby aiming to better health outcomes globally. The Treatment Mobile app and intelligent assistant are set to launch in selected North American clinics in 2022.

Treatment.com International has announced the first sale of its Treatment Primary Care Module, an AI-powered solution designed to enhance patient-doctor interactions in medical clinics. This innovative system allows for efficient pre-interviewing of patients, leading to improved diagnosis and treatment recommendations. The partnership with Dr. Rob Scott's clinic signifies a transformative step for AI in healthcare. The company aims to roll out more products in the future, enhancing its presence in the healthcare technology sector.

Treatment.com International Inc. (CSE: TRUE; OTC: TREIF) has announced the beta launch of its Treatment Digital Health App, driven by a proprietary AI platform. This app aims to provide up-to-date health information to users, enhancing decision-making during ongoing health crises like COVID. Built by a global team of doctors, the app is expected to personalize health recommendations for users. The beta is exclusive, with a broader U.S. launch planned for the new year. Treatment.com focuses on integrating advanced medical protocols into user-friendly applications.